加速分割放疗同步卡培他滨化疗治疗晚期鼻咽癌

背景与目的:目前,常规分割放疗治疗晚期鼻咽癌疗效不甚理想,5年生存率仅在23%～40%之间。为此,本研究探讨加速分割放疗同步卡培他滨化疗治疗晚期鼻咽癌的疗效和毒副反应。方法:82例晚期鼻咽癌患者,采用抽签法随机分为加速分割放疗同步卡培他滨化疗组和常规分割放疗组。同步放化疗组每周照射6d,每天照射1次,每次照射剂量为1.8～1.9Gy,总剂量为72～76Gy,且在放疗同时给予卡培他滨化疗;常规分割放疗组每周照射5d,每天照射1次,每次照射剂量为2Gy,总剂量亦为72～76Gy。结果:同步放化疗组的完全缓解率为92.7%,显著高于常规分割放疗组的71.0%(P<0.05)。同步放化疗组的局部复发率(17.1%)显著低于常规分割放疗组(36.5%)(P<0.05),而其远处转移率(19.5%)亦显著低于常规分割放疗组(41.5%)(P<0.05)。两组的5年生存率分别为63.5%和41.3%,同步放化疗组显著优于常规分割放疗组(P<0.05)。而同步放化疗组的骨髓抑制及急性放射反应发生率则显著高于常规分割放疗组(P<0.05)。结论:加速分割放疗同步卡培他滨化疗对晚期鼻咽癌有较好的疗效,且其毒副反应能耐受。     

后程加速超分割配合后程化疗治疗食管癌80例临床观察

目的观察后程加速超分割放疗配合后程化疗对食管癌的临床疗效及毒副反应。方法对80例食管鳞癌患者随机分为两组：后程加速超分割组（后超组）和后程加速超分割加后程化疗组（综合组）。后超组40例，每次180～200cGy，每周5次，共4000cGy／4w，第5周开始起每次140～150cGy，每日2次，间隔6小时，照射量2400～2800cGy／2w。综合组40例，放疗方法同后超组，放疗开始第5周化疗，具体用药如下：5-FU 0．25g静滴，第1～10天，DDP10mg静滴，第1～10天，治疗期间配合使用升白、止吐等治疗。结果3年局控率分别为52．5％及65．0％。1、2、3年生存率分别为70．0％、52．5％和40．0％及82．5％、67．5％和57．5％。综合组的急性放射性食管炎及气管炎高于后超组（P〈0．05）。结论后程加速超分割加同期化疗能进一步提高食管癌患者1、2、3年生存率，但近期放射反应较重。     

食管癌后程加速超分割放射治疗的中期疗效分析

目的：比较后程加速超分割及后程加速超分割联合化疗与常规分割放疗食管癌的疗效与毒副作用。方法：将120例患者随机分为3组：后程加速超分割（late course fractionation radiotherapy，LCAF）组；后程加速超分割协同化疗（LCAF＋C）组；常规分割放疗（conventional fractionation radiotherapy，CF）组。根据治疗和随访结果分析3个组1、2、3年的生存率和局部控制率。结果：所有患者都完成了全部治疗，LCAF组和LCAF＋C组的生存率和局控率均优于CF组（P〈0．01），而LCAF组和LCAF＋C组间差异无显著性（P〉0．05）。急性毒副作用LCAF＋C组最重，CF组最轻。LCAF组和LCAF＋C组死于局部未控或复发率明显低于CF组，而肿瘤远处转移率在3组间无明显差异（P=1．00）。结论：LCAF组和LCAF＋C组均能显著提高食管癌的局部控制率和生存率；同期小剂量化疗没有降低远处转移率。     

常规、后超外照射及外照加腔内照射治疗中晚期食管癌的疗效分析

目的:观察和比较常规分割、后程加速超分割外照射及外照射加腔内照射三种方法治疗中晚期食管癌的疗效及其放射反应。方法:从1994年5月至1995年6月对111例中晚期食管癌患者进行了常规分割外照射、后程加速超分割放疗及常规外照射加腔内近距离照射的随机分组研究。所有病例均为鳞癌,无锁骨上淋巴结转移及远处转移,年龄在40～75岁。常规分割照射组(常规组)40例:6000cGy/30次·6周,每日1次,1次200cGy,每周5天。后程加速超分割组(后超组)41例:前3周常规分割,3000cGy/15次·3周,后2周加速超分割照射,3000cGy/20次·2周,每日2次,每次150cGy,每周5天。外照射加腔内照射组(外加内组)30例;常规外照射至3500cGy时行腔内照射,外照射不停(仅内照射当天停1次),内照射500cGy/次,1次/周,内照2次共1000cGy,外照射总量为5000cGy。所有病例随访达3年。结果:常规组、后超组及外加内组的1～3年生存率分别为57.5%、56.1%、53.3%和22.5%、29.3%、26.7%,各组生存率相比无统计学差异。3组食管炎发生率分别为22.5%、41.5%和50.0%,后超组及外加内组的食管炎发生率较高。结论:后程加速放疗及外照射加内照射治疗中晚期食管癌均未能明显提高生存率,且食管炎发生率较高,具体哪一种照射方法为最佳治疗方案,下结论仍为时过早,有待累计大宗     

后程加速超分割放疗和辅助化疗治疗鼻咽癌的临床研究

观察鼻咽癌（NPC）后程加速超分割放疗和辅助化疗的急性反应及近期疗效。方法　按随机方法将26例早期（Ⅰ～Ⅱ期）NPC分为常规分割放疗组及后程加速超分割放疗组，54例晚期（Ⅲ～Ⅳ期）NPC分为常规分割放疗组，后程加速超分割放疗组及后程加速超分割放疗辅助化疗组。结果后程加速超分割放疗辅助化疗组原发肿瘤肉眼消失剂量明显低于未加化疗的其它二组（P＜0．05），各组急性反应程度无明显差异（P＞0．05），而后程加速超分割放疗（包括辅助化疗组）组治疗结束时肿物残存率与常规放疗组相比有下降趋势。结论后程加速超分割放疗和辅助化疗可能为NPC治疗的一种较好的方法，值得进一步研究。     

骨转移癌不同放疗分割方法的止痛作用探讨

目的 探讨关于局部野放射治疗骨转移癌的不同分割方法的止痛效果。方法 97例患者,40例采用常规分割照射,Dr 200 cGy/次,每周5次,Dr 3600-5000 cGy;57例采用低分割照射,DT300-500 cGy/次,每周3-5次,Dr 2000-3000 cGy。结果 放疗起到了明显的止痛作用,常规分割放疗组与低分割放疗组止痛效果大致相似,差异无显著性(P>0.05)。结论 骨转移癌的放射治疗应根据病情来决定。对一般情况好,预计生存期长的患者应积极给予全剂量的分割治疗,而对于病情相对较重、行动又不方便、预计生存期短的患者,应采取低分割照射,同样可以起到止痛作用。     

后程加速超分割放疗配合化疗治疗食管癌的临床疗效

目的　观察后程加速超分割放射治疗配合化疗对食管癌的临床疗效及毒副反应。方法　自 1998年 6月至 2 0 0 0年 6月对 16 0例食管鳞癌病人随机分为两组 :后程加速超分割组 (后超组 )和后程加速超分割加化疗 (综合组 )。后超组 80例 ,每次 180～ 2 0 0Gy ,每周 5次 ,共 4 0 0 0cGy/ 4周 ,第 5周开始起每次 15 0Gy ,每日 2次 ,间隔 6小时 ,照射量 2 4 0 0～ 30 0 0cGy/ 2周。综合组 80例 ,放疗方法同后超组 ,放疗开始第 1周化疗 ,具体用药如下 :5 -Fu0 2 5静脉滴注 ,第 1～ 10天 ,DDP10mg静脉滴注 ,第 1～ 10天 ,治疗期间配合使用升白抗炎支持等治疗。结果　后超组及综合组 3年局控率分别为 5 2 5 %及 6 5 %。 1、2、3年生存率分别为 70 %、5 2 5 %、4 0 %及 82 5 %、6 7 5 %、5 7 5 %。综合组的急性放射性食管炎及气管炎高于后超组 (P <0 0 5 )。结论　后程加速超分割加同期化疗能进一步提高食管癌病人 1、2、3年生存率 ,但近期放射反应较重。     

局部晚期鼻咽癌三种治疗模式比较研究

 目的 探讨三种模式治疗局部晚期鼻咽癌的临床疗效、治疗反应及生存质量。方法 2001年1月至2002年6月初治的病理确诊的局部晚期鼻咽癌120例随机分为两组：同期放化疗（RC）组60例，放疗每周照射5 d，1次／d，200 cGy／次，总剂量7 000～8 000 cGy，化疗方案为5-Fu+DDP，在放疗第1、4周各用1周期；放疗艾迪（RAD）组60例，放疗方式同RC组，用艾迪注射液50 ml静脉滴注，连用10 d为l周期，间隔7 d重复，共用3个周期。同期由于各种原因仅单纯放疗（R）而临床资料与上述两组具有可比性的患者60例作为对照组。观察各组治疗效果和放射反应。结果 随访3年，RC组和RAD组3年生存率近似（73.3 %，65.0 %，P = 0.347），高于R组（53.3 %，P＝0.028），局部复发率RC组与RAD组近似（10.0 %，18.3 %，P＝0.294 4），低于R组（26.7 %，P＝0.033 6）；急性和后期放射反应RC组最重，RAD组最轻（P＜0.05）；RAD组生活质量最好（P＜0.01）。结论 放疗加艾迪注射液和放疗加同期化疗可以降低晚期鼻咽癌的局部复发率，提高生存率，均优于单纯放疗。     

加速分割放射治疗鼻咽癌的临床研究

目的 :探讨加速分割放射治疗鼻咽癌的治疗效果、放射反应和并发症。方法 :研究1993年 6月— 1996年 6月经病理证实首程接受加速分割放疗的 16 8例鼻咽癌患者的局部复发率、 5年生存率、放射反应及并发症 ,并与同期接受常规分割放疗的 170例鼻咽癌患者进行对比研究。加速分割组 (研究组 )每周照射 6天 ,每天 1次 ,每次 185 c Gy～ 190 c Gy,总剂量 740 0 c Gy～ 76 0 0 c Gy/39f～ 41f,共 46天～ 48天 ,常规分割组 (对照组 )每周照射 5天 ,每天 1次 ,每次 2 0 0 c Gy,总剂量 70 0 0 c Gy～ 75 0 0 c Gy,预防剂量 5 0 0 0 c Gy～ 5 5 0 0 c Gy。结果 :随访超过 5年 ,研究组与对照组的局部复发率分别为 13.7% (2 3/16 8)和 2 6 .5 % (45 /170 ) (P<0 .0 1) ,5年生存率分别为 5 9.5 % (10 0 /16 8)和 48.8% (83/170 ) (P<0 .0 5 )。 度急性放射反应分别为 48.8% (82 /16 8)和 33.5 % (5 7/170 )(P<0 .0 1) ,并发症发生率研究组明显低于对照组。结论 :加速分割放射治疗鼻咽癌的疗效优于常规放射治疗 ,患者能耐受加速分割放射治疗方案。     

放射合并化疗治疗子宫颈癌的临床实验研究

实验研究示放射合并抗癌药对HeLa细胞及裸鼠人宫颈癌移植肿瘤的抑制作用均大于单纯放射。25例Ⅰ_b～Ⅳ期宫颈癌分别接受~(60)Co腔内放疗(A点照射量800cGy/次)和腔内放疗合并化疗(顺铂30mg/m~2+博莱霉素15mg/m~2),照射后即刻用药,每周1次。结果示合并化疗组(11/25)肿瘤缩小及病理改变明显较单纯放疗组显著,毒副反应不明显。作者认为放射后即刻化疗(顺铂+博莱霉素)治疗子宫颈癌的方案,可能提高晚期宫颈癌的疗效。     

40例椎体骨转移癌的放射治疗观察

目的　探讨常规分割与低分割放射治疗椎体骨转移瘤的效果。方法　 40例病人 ,2 1例采用常规分割 ,DT 2 0 0cGy/次 ,每周 5次 ,DT 3 0 0 0～ 5 0 0 0cGy ;19例采用低分割照射 ,DT 3 0 0～ 60 0cGy/次 ,每周 1～ 3次 ,DT 2 0 0 0～ 3 60 0cGy。结果　放疗起到了明显的止痛作用 ,常规分割放疗组与低分割放疗组止痛效果大致相同 ,无统计学意义 (P >0 0 5 )。但放疗对神经系统损害的恢复效果差。结论　椎体放疗应根据病情及预计生存期长短来决定。对一般情况好 ,预计生存期长的病人应采取积极的治疗 ,给予大剂量长疗程的常规分割 ,而对于那些病情相对较重 ,行动又不方便 ,无望长期生存的病人 ,应采取低分割照射 ,且见效快 ,同样起到止痛作用。椎体骨转移应尽早治疗 ,才可能保全或恢复患者的神经功能。     

大分割放疗治疗恶性肿瘤骨转移癌痛的效果

目的探讨大分割放疗治疗恶性肿瘤骨转移癌痛的效果。方法选取恶性肿瘤骨转移患者87例,采用随机数字表法将患者随机分为大分割组(n=42)和常规分割组(n=45),其中大分割组给予300 cGy/次,每日1次,每周5次,总剂量3000 cGy;常规分割组给200 cGy/次,每日1次,每周5次,总剂量5000 cGy。观察2组放疗疼痛缓解效果、不良反应等。结果大分割组和常规分割组骨痛缓解总有效率分别为88.89%和92.86%,差异无统计学意义(P>0.05)。常规分割组和大分割组放疗后VAS评分分别为(1.41±0.52)分和(1.50±0.48)分,明显低于放疗前(P<0.05)。大分割组放疗后疼痛缓解开始时间为(5.31±1.21)d,明显短于常规分割组(7.52±1.34)d(P<0.05)。常规分割组和大分割组放疗后卡氏评分分别为(80.15±6.20)分和(81.40±6.72)分,明显高于放疗前(P<0.05)。大分割组消化道不良反应程度高于常规分割组(P<0.05)。结论大分割放疗和常规分割放疗治疗恶性肿瘤骨转移癌痛的效果相当,其中大分割放疗具有止痛起效快的特点,但其引起的消化道不良反应也较多,治疗方案应根据患者具体病情合理选择。     

后程加速超分割放射治疗I～II期鼻咽癌的疗效观察

目的：观察后程加速超分割放射治疗早期鼻咽癌的临床疗效、毒副反应及后遗症。方法：将108例I～II期鼻咽癌患者随机分为常规分割放疗组(常规组)和后程加速超分割放疗组(后超组),每组54例。常规组照射2Gy/次,5次/周,总量为70Gy/7周。后超组前3.5周照射同常规组,然后开始1.5Gy/次,2次/日,间隔6h,总量为69Gy/6周。结果：鼻咽部肿瘤消退率：常规组为70.97％(22/31),后超组为89.47％(34/38),但两组差别无显著性意义(P=0.05);颈部淋巴结完全消退率：常规组为86.67％(26/30),后超组为90.91％(30/33),两组差别无显著性意义(P>0.05);两组1、2、3年生存率分别为96.12％、80.97％、78.55％和98.13％、93.95％、90.87％(P=0.06),无明显的统计学差异;两组放疗毒副反应及后遗症也无显著性差别(P>0.05)。结论：I～II期鼻咽癌后程加速超分割放疗疗效未见优于常规分割放疗,但未加重放疗毒副反应及增加放疗后遗症,有必要扩大病例并作长期随访研究。     

Accelerated radiotherapy for T1, 2 glottic carcinoma: analysis of results with KI-67 index

PURPOSE: Hyperfractionated and accelerated radiotherapy without a split was performed to improve the local control probability of early glottic carcinomas. We analyzed the results of this regimen by using the Ki-67 index. METHODS AND MATERIALS: Over a 12-year period, 85 T1N0M0 glottic cancers and 50 T2N0M0 glottic cancers were treated with conventional fractionation (CF) from 1984 to 1989 and with accelerated fractionation (AF) since 1990. The CF program consisted of five daily fractions of 2 Gy per week, for a total of 64 Gy. The AF program consisted of 1.72 Gy per fraction, two fractions per day, 5 days a week, for a total of 55 or 58 Gy. The specimens, taken before radiotherapy, were immunohistochemically stained with anti-Ki-67 antibody. RESULTS: The 5-year local control probability for T1 tumors was 79.6 +/- 6.9% with CF treatment, whereas with AF it was 86.9 +/- 5.6%. For T2 tumors it was 62.7 +/- 12.2% with CF, whereas it was 74.7 +/- 7.8% with AF. The difference between CF and AF did not reach the point of statistical significance. However, when T1 tumors had a Ki-67 index lower than 50%, the local control rate achieved with AF was significantly better than that with CF (p = 0.018). When the tumors had a Ki-67 index that was 50% or more, there was no difference in the local control rate between CF and AF, whether they were T1 or T2. The peak mucosal reactions at the larynx and/or hypopharynx were much more severe and appeared at smaller doses and earlier in AF than in CF. The patients with AF showed no severe late complications. CONCLUSIONS: AF could not obtain statistically significant improvement in local control probability of T1 or T2 glottic carcinomas.     

Multiple daily fractionated radiation therapy and misonidazole in the management of malignant astrocytoma. A preliminary report

Various attempts have been made to improve the effectiveness of radiation in the treatment of cerebral malignant astrocytomas. A trend favoring multiple daily fractionated (MDF) radiation therapy over conventional single daily fractionated (CF) radiation therapy was identified in our previous study. In order to assess the effect of MDF with and without misonidazole, a province-wide prospective randomized trial was initiated in January 1981. By March 1984, 124 patients with histologically verified grade III and IV astrocytomas were randomized to CF (5800 cGy/6 weeks/30 fractions), MDF (6141 cGy/4.5 weeks/69 fractions at 89 cGy every 3-4 hours, three times a day) and MDF in combination with misonidazole (1.25 g/m2 three times weekly for the first 3 weeks). Thirty-eight patients were randomized to CF, 43 patients to MDF, and 43 patients to MDF and misonidazole. At the preliminary assessment in July 1984, the median survival time was 27 weeks for the CF group, 39 weeks for the MDF group and 49 weeks for MDF and misonidazole group. The 1-year actuarial survival rate from surgery was 20% for CF group, 41% for MDF group, and 45% for MDF and misonidazole group. There is a statistically significant difference (P less than 0.001) between the CF and MDF group. However, the addition of misonidazole does not significantly alter survival.     

Different risks of symptomatic brain necrosis in NPC patients treated with different altered fractionated radiotherapy techniques

PURPOSE: To report our observation of excessive temporal lobe necrosis in nasopharyngeal carcinoma (NPC) patients treated with 160 cGy b.i.d. radiotherapy technique. During the same period, patients treated with 120 cGy b.i.d. have not shown a similar tendency. Our experience may be useful for designing unconventional radiotherapy regimens for NPC patients. METHODS AND MATERIALS: During the period from October 1991 to January 1998, 81 M0, previously untreated NPC patients completed altered fractionated radiotherapy. Seventy patients were treated with the hyperfractionated technique, and 11 were treated using the accelerated-hyperfractionated scheme. Hyperfractionated radiotherapy was delivered using 120 cGy b.i.d. separated by 6-h intervals throughout the course. A minimum tumor dose of 8000 cGy was the standard dose over an 8-week period. With the accelerated-hyperfractionated scheme, 160 cGy was given twice daily, also with an interval of 6 h. The minimum tumor dose ranged between 6840 and 7640 cGy, with 7 of the 11 patients receiving 7000 cGy. The arrangement of portals was the same for both regimens. The follow-up period for patients alive was from 32 to 102 months with a median of 61 months for the hyperfractionated patients. For the accelerated-hyperfractionated group, it ranged from 67 to 82 months with a median of 72 months. No patient was lost to follow-up. RESULTS: At the time of analysis, 49 of the 70 patients in the hyperfractionated group were alive. In the accelerated group, 8 of the 11 patients were alive. The estimated radiation dose to the temporal lobe for the hyperfractionated group was 6000-7440 cGy with a median of 7080 cGy. For the accelerated-hyperfractionated group, the dose range was 4480-6700 cGy with a median of 6400 cGy. Of the 70 patients treated with hyperfractionated radiotherapy, none developed symptomatic brain necrosis, despite the higher total dose to the temporal lobe in general. In contrast, 3 of the 11 (27%) patients irradiated using the accelerated-hyperfractionated regimen suffered from temporal lobe necrosis at 16, 19, and 40 months after completion of radiotherapy. CONCLUSION: An excessive incidence of temporal lobe necrosis was noted when an accelerated-hyperfractionated regimen with 160 cGy b.i.d. was used in NPC patients with a median brain dose of 6400 cGy. There has been no such event in patients treated using a hyperfractionated regimen with 120 cGy and a median brain dose of 7000 cGy. The real causes of this discrepancy are not known. However, a high sensitivity of the human brain to a change in fraction size may play a role.     

Late course accelerated fractionation in radiotherapy of esophageal carcinoma.

PURPOSE: To evaluate the efficacy of adding accelerated fractionation after completing two thirds of routine fractionated radiotherapy in esophageal carcinoma. METHODS AND MATERIALS: From April 1988 to April 1990, 85 patients with histologically confirmed carcinoma of the esophagus were randomized into two groups. (1) The conventional fractionation (CF) group, received 1.8 Gy per day five times a week to a total dose of 68.4 Gy in 7-8 weeks, and (2) the late course accelerated hyperfractionated (LCAF) group which received the same schedule as the CF group during the first two thirds of the course of radiotherapy to a dose of 41.4 Gy/23 fx/4 to 5 weeks. This was then followed by accelerated hyperfractionation using reduced fields. In the LCAF portion of the radiotherapeutic course, the irradiation schedule was changed to 1.5 Gy twice a day, with an interval of 4 h between fractions, to a dose of 27 Gy/18 fx. Thus the total dose was also 68.4 Gy, the same as the CF group, but the course of radiotherapy was shorter, being only 6.4 weeks. The same Cobalt 60 teletherapy unit was used to treat all the cases. RESULTS: The 5 year actuarial survival and disease-free survival rates in the LCAF group were 34% and 42%, as compared to 15% and 15% respectively in the CF group, all statistically significant. Better local control was seen in the LCAF group than in the CF group, the 5 year control rates being 55% versus 21% (P = 0.003). The acute reactions were increased but acceptable in the LCAF patients, the radiation treatments could be completed without any breaks. The late reactions as observed after 5 years were not increased in comparison with the CF patients. CONCLUSIONS: The results from this study show that the late course accelerated hyperfractionated radiotherapy regime can improve results in esophageal carcinoma, with acceptable acute reactions as compared to conventional radiotherapy.     

Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma

PURPOSE: To compare the benefit achieved by concurrent chemoradiotherapy (CRT) and/or accelerated fractionation (AF) vs. radiotherapy (RT) alone with conventional fractionation (CF) for patients with T3-4N0-1M0 nasopharyngeal carcinoma (NPC). METHODS AND MATERIALS: All patients were irradiated with the same RT technique to > or =66 Gy at 2 Gy per fraction, conventional five fractions/week in the CF and CF+C (chemotherapy) arms, and accelerated six fractions/week in the AF and AF+C arms. The CF+C and AF+C patients were given the Intergroup 0099 regimen (concurrent cisplatin plus adjuvant cisplatin and 5-fluorouracil). RESULTS: Between 1999 and April 2004, 189 patients were randomly assigned; the trial was terminated early because of slow accrual. The median follow-up was 2.9 years. When compared with the CF arm, significant improvement in failure-free survival (FFS) was achieved by the AF+C arm (94% vs. 70% at 3 years, p = 0.008), but both the AF arm and the CF+C arm were insignificant (p > or = 0.38). Multivariate analyses showed that CRT was a significant factor: hazard ratio (HR) = 0.52 (0.28-0.97), AF per se was insignificant: HR = 0.68 (0.37-1.25); the interaction of CRT by AF was strongly significant (p = 0.006). Both CRT arms had significant increase in acute toxicities (p < 0.005), and the AF+C arm also incurred borderline increase in late toxicities (34% vs. 14% at 3 years, p = 0.05). CONCLUSIONS: Preliminary results suggest that concurrent chemoradiotherapy with accelerated fractionation could significantly improve tumor control when compared with conventional RT alone; further confirmation of therapeutic ratio is warranted.     

全程超分割放射治疗食管癌126例

目的评价食管癌全程低剂量超分割放射治疗的临床疗效。方法2000年1月至2001年12月治疗的食管癌患者126例，采用全程超分割放射治疗，120～140cGy／次，2次／d，5d／周，放疗总量6400～7400cGy。结果近期有效率达99．21％，1年生存率61．11％，2年生存率41．27％，5年生存率23．02％；中位生存期1．29年；1年无进展生存（PFS）率57．94％，2年PFS率38．10％，5年PFS率19．84％；中位无进展生存期（TTP）1．16年。结论全程超分割放射治疗食管癌疗效较好，但有待大规模临床试验证实。